Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma With Nonclear Cell Histology

Journal of Urology

Volumn 178, Issue 5, 2007, Pages 1896-1900

  Kassouf, Wassim ^a   Sanchez Ortiz, Ricardo ^b   Tamboli, Pheroze ^c   Tannir, Nizar ^c   Jonasch, Eric ^c   Merchant, Madhur M ^c   Matin, Surena ^c   Swanson, David A ^c   Wood, Christopher G ^c  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b UNIVERSITY OF PUERTO RICO SCHOOL OF MEDICINE   (Puerto Rico)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

carcinoma; comparative; histology; kidney; neoplasm metastasis; nephrectomy; renal cell

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CISPLATIN; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; FLUOROURACIL; GEMCITABINE; HEAT SHOCK PROTEIN; INTERFERON; INTERLEUKIN 2; METHOTREXATE; N ACETYLSARCOSYLGLYCYLVALYL DEXTRO ALLOISOLEUCYLTHREONYLNORVALYLISOLEUCYLARGINYLPROLINE ETHYLAMIDE; THALIDOMIDE; VINBLASTINE;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CLEAR CELL CARCINOMA; CYTOREDUCTIVE SURGERY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KAPLAN MEIER METHOD; KIDNEY CARCINOMA; KIDNEY SARCOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; NEPHRECTOMY; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; STATISTICAL ANALYSIS; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, RENAL CELL; FEMALE; FOLLOW-UP STUDIES; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; NEPHRECTOMY; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TIME FACTORS; UNITED STATES;

EID: 35148856073     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2007.07.037     Document Type: Article

References (19)

1. Storkel S., Eble J.N., Adlakha K., Amin M., Blute M.N., Bostwick D.G., et al. Classification of renal cell carcinoma: Workgroup No. 1. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer 80 (1997) 987
2. Jemal A., Siegel R., Ward E., Murray T., Xu J., and Thun M.J. Cancer statistics, 2006. CA Cancer J Clin 56 (2006) 106
3. Flanigan R.C., Mickisch G., Sylvester R., Tangen C., van Poppel H., and Crawford E.D. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol 171 (2004) 1071
4. Mickisch G.H., Garin A., van Poppel H., de Prijck L., Sylvester R., and European Organisation for Research and Treatment of Cancer (EORTC) Genitourinary Group. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 358 (2001) 966
5. Flanigan R.C., Salmon S.E., Blumenstein B.A., Bearman S.I., Roy V., and McGrath P.C. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 345 (2001) 1655
6. Levy D.A., Swanson D.A., Slaton J.W., Ellerhorst J., and Dinney C.P. Timely delivery of biological therapy after cytoreductive nephrectomy in carefully selected patients with metastatic renal cell carcinoma. J Urol 159 (1998) 1168
7. Walther M.M., Yang J.C., Pass H.I., Linehan W.M., and Rosenberg S.A. Cytoreductive surgery before high dose interleukin-2 based therapy in patients with metastatic renal cell carcinoma. J Urol 158 (1997) 1675
8. Fallick M.L., McDermott D.F., LaRock D., Long J.P., and Atkins M.B. Nephrectomy before interleukin-2 therapy for patients with metastatic renal cell carcinoma. J Urol 158 (1997) 1691
9. Rackley R., Novick A., Klein E., Bukowski R., McLain D., and Goldfarb D. The impact of adjuvant nephrectomy on multimodality treatment of metastatic renal cell carcinoma. J Urol 152 (1994) 1399
10. Wood C.G. The role of cytoreductive nephrectomy in the management of metastatic renal cell carcinoma. Urol Clin North Am 30 (2003) 581
11. Motzer R.J., Bacik J., Murphy B.A., Russo P., and Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 20 (2002) 289
12. Motzer R.J., Bacik J., and Mazumdar M. Prognostic factors for survival of patients with stage IV renal cell carcinoma: Memorial Sloan-Kettering Cancer Center Experience. Clin Cancer Res 10 (2004) 6302S
13. Motzer R.J., Bacik J., Schwartz L.H., Reuter V., Russo P., Marion S., et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 23 (2004) 454
14. Han K.R., Pantuck A.J., Bui M.H., Shvarts O., Freitas D.G., Zisman A., et al. Number of metastatic sites rather than location dictates overall survival of patients with node-negative metastatic renal cell carcinoma. Urology 61 (2003) 314
15. Motzer R.J., Bacik J., Mariani T., Russo P., Mazumdar M., and Reuter V. Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. J Clin Oncol 20 (2002) 2376
16. Beck S.D., Patel M.I., Snyder M.E., Kattan M.W., Motzer R.J., Reuter V., et al. Effect of papillary and chromophobe cell type on disease-free survival after nephrectomy for renal cell carcinoma. Ann Surg Oncol 11 (2004) 71
17. Vasselli J.R., Yang J.C., Linehan W.M., White D.E., Rosenberg S.A., and Walther M.M. Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma. J Urol 166 (2002) 68
18. Pantuck A.J., Zisman A., Dorey F., Chao D.H., Han K.R., Said J., et al. Renal cell carcinoma with retroperitoneal lymph nodes. Impact on survival and benefits of immunotherapy. Cancer 97 (2003) 2995
19. Ronnen E.A., Kondagunta G.V., Ishill N., Spodek L., Russo P., Reuter V., et al. Treatment outcome for metastatic papillary renal cell carcinoma patients. Cancer 107 (2006) 2617